Determinants of Plasma 25-Hydroxyvitamin D Concentrations among Breast Cancer Survivors in Korea

Abstract

We identified demographic, lifestyle, and clinical factors associated with vitamin D status among breast cancer survivors. The vitamin D prediction model may be a useful surrogate of circulating 25-hydroxvitamin D (25(OH)D) concentrations when this measure was not available. We included a total of 216 Korean breast cancer survivors aged 21–79 years who had been diagnosed with stage I to III primary breast cancer and had breast cancer surgery at least 6 months before enrolment. We used linear and logistic regressions to identify determinants for the plasma 25(OH)D concentrations and vitamin D insufficiency (plasma 25(OH)D concentration < 50 nmol/L). We observed that 48.85% of breast cancer survivors had a plasma 25(OH)D concentration less than 50 nmol/L. We identified the following determinants for plasma 25(OH)D concentrations: time since diagnosis (β = −0.005 for 1 month increment), supplementary vitamin D intake (β = 0.06 for 10 μg/day increment), season of the blood draw (β = 0.35 for summer; β = 0.32 for fall; β = 0.26 for winter vs. spring), smoking status (β = 0.28 for former vs. never), use of any supplement (β = −0.35 for non-use vs. use), and the parity number (β = −0.30 for three or more vs. one) were associated with the plasma 25(OH)D concentrations. In addition to the aforementioned variables, body mass index (BMI) was associated with the prevalence of vitamin D insufficiency. We identified the determinants for the plasma 25(OH)D concentrations among Korean breast cancer survivors. Future studies are needed to investigate the role of vitamin D in the progression of breast cancer among Korean breast cancer survivors.

Clinical Implications of Serum 25-Hydroxyvitamin D Status after 5-Year Adjuvant Endocrine Therapy for Late Recurrence of Hormone Receptor-positive Breast Cancer

“…However, these risk factors are generally unmodifiable factors. In contrast, our results indicate that insufficient serum 25(OH)D after the 5-year adjuvant endocrine therapy is a significant risk factor for late recurrence, which can be improved through medication and patient lifestyle modification [ 25 ]. We have thus identified a modifiable risk factor for late recurrence among HR-positive breast cancer patients.…”

Association of lipid profile with obesity among breast cancer survivors: a cross-sectional study

“…Recruitment and data collection of socio-demographic and lifestyle factors, health-behaviour, quality of life, dietary intake and clinical characteristics of participants in this study has been reported elsewhere [19][20][21][22][23]. Participants provided information on socio-demographic factors, including age (in years), marital status, and level of education.…”

Micronutrients and Breast Cancer Progression: A Systematic Review

“…In general, calcitriol alters ROS equilibrium in cancer, reduces cancer proliferation, and has a relevant role in apoptosis and autophagy [38][39][40]. It appears that high serum levels are associated with better survival and DFI [41][42][43][44][45]. In 2010, the Institute of Medicine of the US National Academy of Sciences recommended an intake of 600 IU/day of Vit D (15 µg) to maintain adequate serum 25(OH)D for normal bone mineralization.…”